Pregestational Diabetes in pregnancy
-
Upload
sujoy-dasgupta -
Category
Health & Medicine
-
view
421 -
download
0
Transcript of Pregestational Diabetes in pregnancy
OVERT OVERT DIABETESDIABETES
Classic signs/ symptoms of DM + RBS >200 mg/dl FBS ≥126 mg/dl 2 hr PPBS ≥200 mg/dl
PRE-CONCEPTIONAL CAREPRECONCEPTIONAL COUNSELING
Good glycaemic control before pregnancy can reduce (but not eliminate) the risk of adverse pregnancy outcomes
Regular glucose monitoring Diet, body weight and exercise Weight reduction if BMI > 27 kg/m2 The importance of planning of pregnancy and the
role of contraception Folic acid (5 mg/day) until 12 weeks of gestation to
reduce the risk of NTD
PRE-CONCEPTIONAL CARE (CONTD.)GLYCAEMIC CONTROL
Glucometer for self-monitoring of blood glucose Pre-conceptional Glucose level (ADA,1999a)
FBS 70-100 mg/dl PPBS (1 hr) <140 mg/dl PPBS (2 hr) <120 mg/dl
HbA1c ≤6% Within 3 SD of normal mean If ≥10%, strongly advised to avoid pregnancy (NICE, 2008)
Testing of ketone by strips if they become hyperglycaemic or unwell.
PRE-CONCEPTIONAL CARE (CONTD.)DRUGS (NICE, 2008)
Metformin- can be used in the pre-conception period and during pregnancy, when the likely benefits from improved glycaemic control outweigh the potential for harm
All other OHAs- should be discontinued before pregnancy except Glyburide
Aspart & Lispro insulin- no adverse effects in pregnancy NPH insulin- the first choice for long-acting insulin in
pregnancy ACE inhibitors and ARBs- discontinued before conception
or as soon as pregnancy is confirmed Statins- discontinued before pregnancy or as soon as
pregnancy is confirmed
PRE-CONCEPTIONAL CARE (CONTD.)RETINAL ASSESSMENT (NICE, 2008)
Done at the first appointment Thereafter annually, if no diabetic retinopathy is found By digital imaging with mydriasis using tropicamide Women should defer rapid optimisation of glycaemic
control until after retinal assessment and treatment have been completed
PRE-CONCEPTIONAL CARE (CONTD.)RENAL ASSESSMENT (NICE, 2008)
Includes measurement of microalbuminuria before pregnancy
Referral to a nephrologist should be considered before discontinuing contraception if Serum creatinine ≥120 µmol/L Estimated GFR <45 ml/min/1.73 m2
MANAGEMENT IN FIRST TRIMESTERDIETARY MANAGEMENT
3 meals and 3 snacks per day
Consistent timing with food intake To facilitate insulin dosage & avoid
hypoglycaemia Specially for NPH + Regular insulin Not so rigorous for Glargine + Aspart/ Lispro
MANAGEMENT IN FIRST TRIMESTER (CONTD.)
INSULIN THERAPY Mainstay of management in type I DM To cover Basal needs (Basal Insulin)- Intermediate/ Long acting Insulin- To suppress hepatic neoglucogenesis between meals & during fasting
PP rise of sugar (Prandial Insulin)- Short acting Insulin
PHARMACOKINETICS OF INSULIN PREPARATIONS
ONSET PEAK (Hrs)
DURATION (Hrs)
SHORT ACTINGLISPRO <15 min 0.5-1.5 3-4ASPART <15 min 0.5-1.5 3-4REGULAR 30-60 min 2-3 4-6INTERMEDIATE ACTINGISOPHANE INSULIN (NPH) 1-3 hr 5-7 13-18INSULIN ZINC SUSPENSION (LENTE)
1-3 hr 4-8 13-20
LONG ACTINGEXTENDED INSULIN ZINC SUSPENSION (ULTRALENTE)
2-4 hr 8-14 18-30
INSULIN GLARGINE 1-4 hr Peakless
24
INSULIN THERAPY (CONTD.)I. Multiple daily SC injections Total daily requirement
0.6 U/kg current weight- 1st trimester0.7 U/kg current weight- 2nd trimester0.9 U/kg current weight- 3rd trimester
Regular + NPH – commonly used 4/6 at breakfast (2/3 NPH, 1/3 Regular) 1/6 before dinner- Regular 1/6 at bed time- NPH To be administered >30 min before meal Mid-morning & mid-afternoon snacks necessary to avoid
hypoglycaemia Glargine + Lispro/ Aspart-
Mimics physiological system Less rigorous timing of meals But Inj Lispro necessary before each meals
INSULIN THERAPY (CONTD.)II. Subcutaneous insulin infusion pump
Only for those women who are highly motivated, where multiple daily injections are ineffective &
no disabling hypoglycaemiaNeeds strict asepsisNeeds less Insulin (0.3-0.5 U/kg)
III. Inhaled Insulin Not well studied in pregnancy Needs PFT monitoring
INSULIN THERAPY (CONTD.) Insulin: Carbohydrate ratio:
One method to calculate prandinal InsulinHow many grams of CHO is covered by 1 U
Regular InsulinInsulin : CHO = 500/ total daily requirementTypically in the range of 10-15
Insulin Sensitivity Factor Estimated drop in blood glucose per unit of Regular
Insulin Equal to 1500/ total daily requirement Amount of supplemental Insulin needed =
difference between actual and desired blood glucose/ sensitivity factor
Useful to make sliding scale
MANAGEMENT IN FIRST TRIMESTER (CONTD.)
BLOOD SUGAR MONITORING Self-monitoring of capillary blood glucose (CBG)
Finger-prick method using a Glucometer Noninvasive- by Iontophoresis
Goals of glucose control (ACOG, 2005) Fasting ≤ 95 mg/dl Premeal ≤ 100 mg/dl 1 Hr PP ≤ 140 mg/dl 2 Hr PP ≤ 120 mg/dl 02.00- 06.00 AM ≥ 60 mg/dl Mean (Average) 100 mg/dl HbA1c ≤ 6 %
BLOOD SUGAR MONITORING (CONTD.) Blood Sugar should be measured in fasting, 1 hr
before meals and at bed time (NICE, 2008)
Rotine use of HbA1C in 2nd and 3rd trimester is not recommended (NICE, 2008)
Ketone should be measured if women feel unwell or hyperglycaemic
MANAGEMENT IN SECOND TRIMESTER Congenital anomaly detection
Vaginal probe USG at 10-14 weeks to detect NTD & Nuchal tranlucency
MSAFP (values lower in DM) at 16-20 weeks to detect NTD
Detailed sonographic examination at 18-20 weeks Fetal echocardiography for the four-chamber view
of the fetal heart and outflow tracts at 20-22 weeks Individualized glycaemic control
Insulin requirement increases after 24 weeks Dietary management continues
Regular antenatal visits
MANAGEMENT IN THIRD TRIMESTER Insulin and dietary control continues Fetal monitoring Ultrasound monitoring Fetal growth and amniotic fluid volume Every 4 weeks from 28 to 36 weeks Routine monitoring of fetal well-being Not recommended before 38 weeks Indications of monitoring of fetal well-being From 28 weeks
Women at risk of IUGR (macrovascular disease and/or nephropathy)
Unstable DM Women requiring >100 U insulin/day
MANAGEMENT IN LABOUR Decision for delivery
To be taken at 36 weeks- Induction vs CS Discussion with patient, keeping respect to her
decision CS often for macrosomia in White class B and C DM is not a contraindication to VBAC
Timing of delivery Stable DM- at 38 weeks Unstable DM- as soon as fetal lung maturity is
attained
MANAGEMENT IN LABOUR (CONTD.) Preterm labour
β-mimetics are to be avoided Nifedipine is preferred drug <32 weeks, intrauterine infections to be
excluded Steroids for lung maturity are not contraindicated
Needs additional insulin Close monitoring
Labour management IVF & insulin for glycaemic control Careful monitoring
MANAGEMENT IN PUERPERIUM CBG should be regularly monitored Often patient needs no insulin in 1st 24 hr Start with ½ to 2/3 of pre-delivery doses of insulin Breastfeeding should be encouraged Risk of hypoglycaemia during breast feeding Infections promptly detected and treated Contraceptive advices
IUCD does not increase infection rate Hormonal contraceptives are avoided in vascular disease Puerperal sterilisation, if suitable
Counseling regarding future pregnancy
INSULIN RESISTANCE Impaired metabolic response to endogenous or
exogenous insulin (ADA)
Peak insulin levels in 3 hr GTT (µU/ml) <100- normal 100-150- mild resistance 150-300- moderate resistance >300- severe resistance
FBS (mg/dl) : fasting insulin (µU/ml) <4.5 C-peptide assay Glucose-clamp technique
METABOLIC SYNDROME Also called syndrome X, Insulin Resistance syndrome
or Deadly Quartet NCEPATP III definition- At least three of the following FBS ≥110 mg/dl Abdominal obesity (waist circumference >35 inch. In
women, >40 inch in men) Triglycerides >150 mg/dl; HDL <50 mg/dl in women, <40 mg/dl in men BP ≥ 130/85 mm Hg
MANAGEMENT IN PREGNANCYDIETARY MANAGEMENT
Like GDM To maintain a calorie intake adequate for
pregnancy but with minimum weight gain Ideal weight gain
Normal weight 25-35 lbOverweight 15-25 lbObese 11-20 lbUnderweight 28-40 lb
MANAGEMENT IN PREGNANCY (CONTD.)
GLYBURIDE Normal weight/ moderately obese Good β-cell functions Duration of DM <5 years
MANAGEMENT IN PREGNANCY (CONTD.)INSULIN THERAPY
Glyburide
+ NPH insulin at bed time (to suppress hepatic neoglucogenesis to lower FBS) Or Glargine in the morning (less hypoglycaemia) Starting dose is 20 U SC usually If CBG values are still elevated, the dose may be ↑
by 5 U every 5 days until adequate control is obtained
MANAGEMENT IN PREGNANCY (CONTD.)
BLOOD SUGAR MONITORING
Self-monitoring of CBG HbA1C Fructosamine <2.6 µmol/L
MANAGEMENT OF LABOUR AND PUERPERIUM
Similar to GDM
DIABETIC NEPHROPATHY Especially in type I Hypertension & proteinuria Risk of Preeclampsia and preterm labour, IUGR Renal assessment to be done in the first ANC visit Referral to a nephrologist - if
Serum creatinine ≥120 µmol/L Total protein excretion >2 g/day
Estimated GFR should not be used in pregnancy Thromboprophylaxis should be considered-
If proteinuria >5 g/day (macroalbuminuria)
DIABETIC RETINOPATHY (DR)
Both in type I & type II DM Pregnancy worsens retinopathy Acute rigorous metabolic control worsens
retinopathy Slows down progression of retinopathy in long term Insulin Lispro may worsen retinopathy (?) Retinopathy is associated with reduced fetal growth
RETINAL CHANGES IN DIABETES Beningn/ Background / Nonproliferative
retinopathy- (White class D) Microaneurysm (first and commonest finding) Blot haemorrhage Serous leak → hard exudates Pre-proliferative retinopathy- Retinal ischaemia/ infarction → Cotton wool exudates Proliferative retinopathy- (White class R) Neovascularisation on retinal surface & vitreous
MANAGEMENT OF RETINOPATHY
DIABETIC NEUROPATHY
Peripheral sensory-motor neuropathy- uncommon in pregnancy
DIABETIC GASTROPATHY- More troublesome in pregnancy Nausea, vomiting, nutritional problems Difficult glucose control Needs Metoclopramide, H2 receptor blockers,
Erythromycin or Intermittent gastric intubation
INFECTIONS Urinary tract infections
Associated with preterm labour May cause pyelonephritis Screening and treatment of asymptomatic
bacteruria to be done Respiratory tract infections Vulvovaginal infections Puerperal pelvic infections Wound infections after Caesarean Section Needs prompt diagnosis and treatment with
antibiotics
DIABETIC KETOACIDOSIS (DKA) Most serious complication Affects 1% of diabetic pregnancies Fetal loss 20% Unique to type I DM Precipitating factors
Hyperemesis gravidarum Noncompliance to insulin therapy Tocolytics, corticosteroids
Pregnant women usually develop DKA at lower level of glucose than nonpregnant individuals
DIAGNOSIS OF DKA
Blood glucose >250 mg/dl usually Ketone bodies in urine & plasma Arterial pH <7.3 Serum bicarbonate <15 mEq/L
MANAGEMENT OF DKA(ACOG 2005)
Laboratory assessment ABG, glucose, ketones, eletrolytes every 1-2 hr
Insulin IV loading 0.2-0.4 U/Kg IV maintenance 2-10 U/hr
Fluids Isotonic NaCl 1 L in 1st hr 500-1000 ml/hr for next 2-4 hr 250 ml/hr until 80% replaced Total replacement in 1st 12 hrs of 4-6 L
MANAGEMENT OF DKA (CONTD.) Glucose
When CBG <250 mg/dl, 5%DNS infusion Potassium
If initially normal/ low- 15-20 mEq/ hr If elevated, wait, until it becomes normal, then
20-30 mEq/ L IV solution Bicarbonate
If pH < 7.1, add 1 amp (44 mEq) to 1 Lit of 0.45% NS
HYPEROSMOLAR NONKETOTIC COMA
Peculiar to type II DM Severe hyperglycaemia (>600 mg/dl) Serum hyperosmolarity (>320 mOsm/L) No ketonaemia Management- Aggressive fluid therapy to combat
severe dehydration Insulin PotassiumRarely seen in pregnancy
HYPOGLYCAEMIA Especially occurs in 1st trimester with type I DM Peak incidence at 10-15 weeks Significant hypoglycaemia occurs when CBG
values are less than 35 mg/dl Woman should know symptoms of hypoglycaemia Management
Oral glucose If unconscious- 20 ml of 50% dextrose, followed
by 10% dextrose drip If severe, injection Glucagon 1 mg IM/ SC
FASTING HYPERGLYCAEMIASOMOGYI’S PHENOMENON
High fasting blood sugar & C/O nightmares/ nocturnal sweating
Nocturnal hypoglycaemia (01.00- 05.00 AM) → exaggerated counter-regulatory response
Treatment is to DECREASE the night dose of intermediate/ long acting insulin
DAWN PHENOMENON High fasting blood sugar in absence of nocturnal
hypoglycaemia Cause not known exactly Treatment is to INCREASE the night dose of
intermediate/ long acting insulin
THANK YOUTHANK YOU